FDA — authorised 12 February 2026
- Application: NDA219474
- Marketing authorisation holder: ACROTECH BIOPHARMA
- Local brand name: ADQUEY
- Indication: OINTMENT — TOPICAL
- Status: approved
🇺🇸 Moizerto in United States
FDA authorised Moizerto on 12 February 2026
Marketing authorisations
FDA
- Status: approved
Moizerto in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology approved in United States
Frequently asked questions
Is Moizerto approved in United States?
Yes. FDA authorised it on 12 February 2026; FDA has authorised it.
Who is the marketing authorisation holder for Moizerto in United States?
ACROTECH BIOPHARMA holds the US marketing authorisation.